Most Read Articles
Dr Margaret Shi, 02 Jan 2020

Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.

Podcast: Prof Robert Brodsky details findings of four of the late-breaking trials at ASH 2017

21 Dec 2017
Professor Robert Brodsky from Johns Hopkins University School of Medicine, and Secretary of ASH, details findings of four of the late-breaking trials: Hokusai VTE-Cancer (dalteparin), Murano (venetoclax), Alcyone (daratumumab), and Hercules (caplacizumab) trials. 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 02 Jan 2020

Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.